We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

ELISA Detects Measles-Specific IgG In Dried Blood Spots

By LabMedica International staff writers
Posted on 19 Aug 2015
Print article
Image: The Labsystem Multiskan MS plate reader (Photo courtesy of Artisan Technology).
Image: The Labsystem Multiskan MS plate reader (Photo courtesy of Artisan Technology).
A novel technique for measuring measles-specific immunoglobulin G (IgG) in capillary dried blood spots (DBS) using a commercial enzyme-linked immunosorbent assay (ELISA) has been validated.

There are many poor, remote areas in Mesoamerica where little is known about population immunity to measles but this data can be significantly enhanced by measuring anti-measles antibody titers, preferably using DBS which are minimally invasive and affordable.

Scientists at the University of Washington (Seattle, WA, USA) working with their colleagues from Mexico, Panama and Nicaragua, tested a new method for analyzing DBS by comparing matched serum and DBS samples from 50 children. The accuracy, precision, and reliability of the procedure were evaluated, and the optimal cut points to classify positive and negative samples were determined. The method was then applied to 1,588 DBS collected during a large survey of children in Mexico and Nicaragua.

Serum samples were assayed for the presence of measles-specific IgG antibodies (family Paramyxoviridae, genus Morbillivirus, species Measles virus) using the HUMAN Worldwide Diagnostics Measles IgG ELISA kit (Wiesbaden, Germany). The plates were processed through a series of incubation, wash, and reaction steps, ultimately resulting in a color change. The degree of color development of each well, which is directly proportional to the measles IgG antibody concentration in the specimen, was measured spectrophotometrically on a Multiskan MS plate reader (Labsystems Diagnostics; Helsinki, Finland).

Measles-specific IgG in serum samples were 62% negative, 10% equivocal and 28% positive. In comparisons with matched serum, DBS results were 100% sensitive and 96.8% specific, and agreed in 46 of 50 (92%) cases. The seroprevalence of measles-specific IgG in the field study was 63.4% in Mexico and 50.7% in Nicaragua. The inter-assay and intra-assay coefficients of variation from kit-provided controls were greater than desired at 24.8% and 8.4%, respectively; however, in predictive simulations the average misclassification was only 3.9%.

The authors concluded that their study establishes that the applied commercial ELISA test can be used to categorize individuals as having measles-specific IgG through analyses of DBS. In support of this contention, this study found that measles-specific IgG values in DBS and matched serum samples were strongly linearly related, highly correlated, and nearly directly equal. Analyzing DBS collected in low-resources settings is a feasible and accurate means of measuring population immunity to measles and should be used to generate objective measures of health status and health system performance. The study was published in the September 2015 issue of the Journal of Medical Virology.

Related Links:

University of Washington 
HUMAN Worldwide Diagnostics 
Labsystems Diagnostics 


New
Gold Member
Rotavirus Test
Rotavirus Test - 30003 – 30073
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Respiratory Bacterial Panel
Real Respiratory Bacterial Panel 2
New
Immunofluorescence Analyzer
MPQuanti

Print article

Channels

Molecular Diagnostics

view channel
Image: The Mirvie RNA platform predicts pregnancy complications months before they occur using a simple blood test (Photo courtesy of Mirvie)

RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms

Preeclampsia remains a major cause of maternal morbidity and mortality, as well as preterm births. Despite current guidelines that aim to identify pregnant women at increased risk of preeclampsia using... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Deliver Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.